BerGenBio

BerGenBio ASA: Registration of share capital reduction

Bergen, 15 August 2024: Reference is made to the stock exchange announcement

made by BerGenBio ASA (the "Company") on 23 May 2024 regarding the Company's

general meeting resolving a share capital decrease by reducing the nominal value

of the Company's shares by NOK 9 from NOK 10 to NOK 1, resulting in a decrease

of the Company's share capital by NOK 351,784,044, from NOK 390,871,160 to NOK

39,087,116.

The resolution was announced by the Norwegian Register of Business Enterprises

on 28 May 2024, whereafter followed a six-week creditor notice period. The

creditor period has been completed without objections.

The share capital reduction has now been registered with the Norwegian Register

of Business Enterprises (Nw.: Foretaksregisteret). Following such registration

the Company's share capital is NOK 39,087,116 divided into 39,087,116 shares and

voting rights, each share with a nominal value of NOK 1.

For further information, please contact:

Martin Olin, CEO, BerGenBio AS

Rune Skeie, CFO, BerGenBio ASA

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including cancer and severe respiratory infections. The

Company is focused on its proprietary lead candidate bemcentinib a potentially

first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC

and severe respiratory infections. BerGenBio is based in Bergen, Norway with a

subsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange

(ticker: BGBIO). For more information, visit www.bergenbio.com.

This information is subject to the disclosure requirements pursuant to Section 5

-8 and 5-12 of the Norwegian Securities Trading Act.

AI Terminal